NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program
NeuroOne secured its first pharmaceutical industry purchase order for the StereoCED™ Drug Delivery Platform, supporting a preclinical large-animal research program for a Tier 1 global pharmaceutical company. The study, expected to begin early next year, combines targeted intracranial drug delivery with EEG recording over implantation periods of less than 30 days — a capability the company says no competing platform offers.
Key figures
- Order type
- first pharmaceutical industry purchase order
- Study start
- preclinical large-animal study expected early next year
- Implantation window
- less than 30 days
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.